China has over 3.5 million new cases of cancer every year, and the anti-tumor drug market has exceeded 100 billion yuan, about half of which is imported. In order to meet urgent needs, in recent years, China has introduced a number of policies to encourage and accelerate the listing of anti-cancer and other innovative drugs. As an example, there is a shortage of drugs and methods for the treatment of multiple myeloma. The domestic marketed drugs are far from meeting the needs of patients. The application for registration of anticancer drugs with obvious clinical advantages has now been included into the scope of priority review and approval, in order to accelerate the import of innovative drugs by changing the application of clinical trials from an approval system to a default one.

China Bio news release, April 28, 2018